Meridian Bioscience Inc
VIVO
VIVO was delisted on the 30th of January, 2023.
165 hedge funds and large institutions have $514M invested in Meridian Bioscience Inc in 2017 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 68 increasing their positions, 43 reducing their positions, and 36 closing their positions.
58% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 43
8% less call options, than puts
Call options by funds: $541K | Put options by funds: $587K
8% less funds holding
Funds holding: 180 → 165 (-15)
23% less capital invested
Capital invested by funds: $665M → $514M (-$151M)
28% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$71.8M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$3.59M |
| 3 |
FAM
Fred Alger Management
New York
|
+$3.23M |
| 4 |
CEI
Clark Estates Inc
New York
|
+$3.17M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$17.8M |
| 2 |
DGI
Discovery Group I
Chicago,
Illinois
|
-$6.02M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$4.31M |
| 4 |
Bank of New York Mellon
New York
|
-$4.02M |
| 5 |
CAM
Capstone Asset Management
Houston,
Texas
|
-$3.29M |
VIVO Hedge Fund Activity: Q1 2017 in Review
165 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q1 2017, worth a combined $514M — down 23% from $665M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of VIVO and 26 opened new positions — a net loss of 10 holders — while 43 trimmed existing stakes and 68 added.
The largest buyer was BlackRock, adding an estimated $71.8M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $17.8M sold.
- 165 institutional investors held Meridian Bioscience Inc (VIVO) as of Q1 2017, down from 180 in Q4 2016.
- Funds reported $514M of Meridian Bioscience Inc stock for Q1 2017, down 23% quarter-over-quarter.
- 26 funds opened new Meridian Bioscience Inc positions in Q1 2017 and 36 closed out, a net change of -10 holders.
- The largest Meridian Bioscience Inc buyer in Q1 2017 was BlackRock, an estimated $71.8M added.
- The largest Meridian Bioscience Inc seller in Q1 2017 was T. Rowe Price Associates, an estimated $17.8M sold.
Based on aggregated 13F filings for Q1 2017.